论文部分内容阅读
目的探讨胰液中K-ras 12密码子点突变联合血清CA199检测与胰腺癌病程的关系。方法测定32例临床及手术证实的胰腺癌患者血清CA199水平,并采用内镜ERCP从胰管收集的胰液标本,聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)检测胰液K-ras 12基因12密码子点突变,分析胰液中K-ras 12密码子点突变及血清CA199联合检测与胰腺癌术后复发的关系。结果(1)胰液中K-ras 12密码子点突变率为56.3%,与肿瘤大小密切相关(P<0.05)。K-ras 12密码子点突变阳性、阴性表达病例3年复发率分别为66.7%和33.3%。(2)高血清CA199水平且K-ras 12密码子点突变阳性病例组3年复发率为69.2%,而低血清CA199且ras阳性病例组3年复发率为20.0%,差异显著(P<0.05)。结论联合胰液中K-ras 12密码子点突变及血清CA199检测可作为判断胰腺癌术后复发的有效指标,多因素分析对胰腺癌术后复发的判断更有价值。
Objective To investigate the relationship between K-ras 12 codon point mutation in pancreatic juice and serum CA199 detection and the course of pancreatic cancer. Methods Serum CA199 levels were measured in 32 cases of clinically and surgically confirmed patients with pancreatic cancer. Pancreatic fluid samples collected from the pancreatic duct by ERCP were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) Ras 12 12-codon point mutation analysis of K-ras 12 codon point mutations in pancreatic juice and serum CA199 joint detection of pancreatic cancer recurrence. Results (1) Mutation rate of K-ras 12 codon in pancreatic juice was 56.3%, which was closely related to tumor size (P <0.05). The 3-year recurrence rates of K-ras 12 codon point mutation positive and negative expression cases were 66.7% and 33.3% respectively. (2) The 3-year recurrence rate was 69.2% in patients with positive CA199 and K-ras 12 codon mutations. The 3-year relapse rate was 20.0% in low serum CA199 and ras positive cases (P <0.05) ). Conclusions Mutation of K-ras 12 codon in pancreatic juice and detection of serum CA199 can be used as an effective index to judge the recurrence of pancreatic cancer. Multivariate analysis is more valuable for judging the recurrence of pancreatic cancer.